Diagnosing and managing inflammatory bowel disease

Practitioner

Volumn 257, Issue 1763, 2013, Pages 13-18

  Assadsangabi, Arash ^a   Lobo, Alan J ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HUMAN; INFLAMMATORY BOWEL DISEASE;

HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84884309719     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Louis E, Collard A, Oger AF et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49: 777-82 (Pubitemid 33096034)
2. Daniel BC, William SJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57
3. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterology 2005;(19 Suppl A):5-36
4. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53 (Pubitemid 43764536)
5. Rubin GP, Hungin AP, Kelly PJ et al. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553-9 (Pubitemid 32011728)
6. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126:1504-17 (Pubitemid 38649869)
7. Henderson P, Hansen R, Cameron FL et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis 2012;18(6):999-1005
8. Andres P, Friedman S. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:255-281 (Pubitemid 29306479)
9. Mowat C, Cole A, Windsor A et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607
10. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955 Oct 29;2(4947):1041-8
11. Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77(4 Pt 2):914- 920 (Pubitemid 9242053)
12. McKee RF, Keenan RA Perianal Crohn's disease - is it all bad news? Dis Colon Rectum1996; (Pubitemid 26050890)
13. Platell C, Mackay J, Collopy B et al. Anal pathology in patients with Crohn's disease. Aust NZ J Surg 1996; 66:5-9 (Pubitemid 126422502)
14. Louis E, Belaiche J, Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease? World J Gastroenterol 2010;16:2600-2603
15. Beaugerie L, Seksik P, Nion-Larmurier I et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-656 (Pubitemid 43374514)
16. National Institute for Health and Care Excellence. CG166. Ulcerative colitis: Management in adults, children and young people. NICE. London. 2013
17. Dignass A, Lindsay J, Sturm A et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management. J Crohn's Colitis 2012; http://dx.doi.org/10.1016/ j.crohns.2012.09.002
18. National Institute for Health and Clinical Excellence. CG152. Crohn's disease: Management in adults, children and young people. NICE. London. 2012
19. National Institute for Health and Clinical Excellence. TA187. Infliximab (review) and adalimumab for the treatment of Crohn's disease. NICE. London. 2010
20. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-413 (Pubitemid 38182297)
21. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142(1):63-70
22. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a crosssectional study from central England. Eur J Gastroenterol Hepatol 2003;15(12):1275-1280 (Pubitemid 39049669)
23. The IBD Standards Group 2009 Quality Care: Service Standards for the healthcare of people who have Inflammatory Bowel Disease (IBD) www.bsg.org.uk/attachments/160-IBDstandards.pdf
24. British National Formulary (65th ed.). British Medical Association and Royal Pharmaceutical Society of Great Britain.March 2013
25. Beaugerie L, Brousse N, Bouvier AM et al for the CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009 Nov 7;374(9701):1617-25
26. Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohns disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81
27. Reinshagen M. Osteoporosis in inflammatory bowel disease. J Crohn's Colitis 2008;2:202-7
28. Compston J, Cooper A, Cooper C et al. Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. National Osteoporosis Guideline Group (NOGG), Updated May 2013. www.shef.ac.uk/ NOGG/ NOGG-Pocket-Guide-for-Healthcare- Professionals.pdf
29. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009 Jun; 3(2)47-91 doi:10.1016/j.crohns.2009.02.010
30. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55
31. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8 (Pubitemid 40590263)
32. Fiore AE, Shay DK, Haber P et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007;56(RR-6):1-54
33. Targonski PV, Poland GA. Pneumococcal vaccination in adults: recommendations, trends, and prospects. Cleve Clin J Med 2007;74:401-406, 408-410, 413-414
34. Bokemeyer B, Hardt J, Hüppe D et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohn's Colitis 2013;7(5):355-68
35. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFFCA) patient survey. J Crohn's Colitis 2007;1:10-20 (Pubitemid 350265728)